Research
Hormonal
SGLT2 inhibitors reduce epicardial fat volume independently of significant weight loss, suggesting a direct lipolytic effect on epicardial tissue.
SGLT2 inhibitors are a key pharmacological option for HFpEF patients. They reduce epicardial fat directly, which may improve heart mechanics and reduce hospitalizations. Discuss with your doctor if SGLT2 inhibitors are appropriate for your condition.
ModerateSupportsMEDIUM confidence
Although the mechanisms of benefit of these drugs are uncertain, they have demonstrated a reduction in epicardial fat despite only minimal weight loss suggesting a direct lipolytic effect on epicardial fat.
Why this rating
Based on observational data and mechanistic studies; randomized trials specifically on EAT reduction are implied but not detailed as primary endpoints.
Source
Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
Mary-Tiffany Oduah et al. · Cardiac failure review · 2023
DOI 10.15420/cfr.2022.25
narrative_reviewCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Epicardial adipose tissue (EAT) contributes to Heart Failure with Preserved Ejection Fraction (HFpEF) through two distinct mechanisms: mechanical pericardial restraint and local inflammatory/fibrotic secretion.Good
- Bariatric surgery is the most effective intervention for reducing epicardial fat volume and improving HFpEF outcomes, superior to modest lifestyle changes.Good
- A Mediterranean-style diet with high unsaturated fats and low carbohydrates reduces epicardial fat volume, whereas a standard low-calorie diet and exercise alone do not.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →